Ray Vaughters, MD
Endocrinology, Diabetes & Metabolism · Aiken, SCNPI 1457327587
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $279,381 of the $321,058 with a category attached, or 87.0%. 55 manufacturers reported payments, led by Lilly USA, LLC at 34.0% of the total. Reporting peaked in 2019 at $108,157 and has fallen 98.1% since, to $2,025 in 2025. Among endocrinology, diabetes & metabolism clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,134 payments — averaging $283.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$109K
- Novo Nordisk$96K
- AstraZeneca$71K
- Mannkind Corporation$34K
- Sanofi-aventis U.S. LLC$1K
- Amgen$1K
- plus $7K from 49 others
What the payments were for
- Consulting fees$3,2501%
- Speaking & faculty fees$279,38187%
- Travel & lodging$18,9896%
- Food & beverage$18,9096%
- Education$5290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRULICITY$82,321
- FARXIGA$69,385
- Ozempic$48,171
- RYBELSUS$42,204
- AFREZZA$33,292
- MOUNJARO$15,754
- Tresiba$1,128
- SOLIQUA 100/33$810
- Korlym$333
- NEXLIZET$109
- NEXLETOL$109
- TZIELD$109
- MINIMED 780G$106
- GVOKE HYPOPEN$102
How this compares
$321,058 in reported general payments places this provider in the 95th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
See all endocrinology, diabetes & metabolism providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 230 | $262,464 |
| FarxigaDapagliflozin Propanediol | 133 | $100,409 |
| JardianceEmpagliflozin | 90 | $86,780 |
| MounjaroTirzepatide | 49 | $52,168 |
| TrulicityDulaglutide | 38 | $44,489 |
| RybelsusSemaglutide | 25 | $26,862 |
| JanuviaSitagliptin Phosphate | 38 | $26,025 |
| Tresiba Flextouch U-100Insulin Degludec | 41 | $19,479 |
| Bydureon BciseExenatide Microspheres | 16 | $13,403 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 16 | $13,298 |
| Novolog FlexpenInsulin Aspart | 43 | $9,386 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $7,479 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $5,951 |
| Humalog Kwikpen U-100Insulin Lispro | 35 | $5,128 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 18 | $3,991 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $96,195 | $289,326255 claims |
| AstraZenecaFarxiga | $71,414 | $100,409133 claims |
| Lilly USA, LLCMounjaro, Trulicity | $109,189 | $96,65787 claims |
| Boehringer IngelheimJardiance | $255 | $86,78090 claims |
| MerckJanuvia, Janumet | $198 | $33,50451 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $27 | $3,169278 claims |
| AbbVieSynthroid | $49 | $1,52515 claims |
| Sanofi-aventis U.S. LLCLantus | $1,396 | $74212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
Other endocrinology, diabetes & metabolism in Aiken
- Gauri DhirMyrtle Beach$417K
- Cory WhiteGreenville$413K
- Louis HaenelCharleston$377K
- Vonda CalcuttWalterboro$368K
- Donald EagertonMyrtle Beach$284K
- Beatrice HullCharleston$214K
- Joseph MathewsSummerville$168K
- Brittany HendersonMount Pleasant$157K
- Zouhair BibiConway$120K
- James HortonGreenville$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.